Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis

Vista sencilla de ítem
dc.contributor.authorSalazar, J.
dc.contributor.authorPirela, D.
dc.contributor.authorNava, M.
dc.contributor.authorCastro, A.
dc.contributor.authorAngarita, L.
dc.contributor.authorParra, H.
dc.contributor.authorDurán-Agüero, S.
dc.contributor.authorRojas-Gómez, D.
dc.contributor.authorGalbán, N.
dc.contributor.authorAñez, R.
dc.contributor.authorChacín, M.
dc.contributor.authorDiaz, A.
dc.contributor.authorVillasmil, N.
dc.contributor.authorDe Sanctis, J.
dc.contributor.authorBermúdez, V.
dc.date.accessioned2022-06-22T14:41:50Z
dc.date.available2022-06-22T14:41:50Z
dc.date.issued2022-03
dc.descriptionIndexación: Scopus.es
dc.description.abstractCardiovascular disease (CVD) is a global public health issue due to its high morbidity, mortality, and economic impact. The implementation of innovative therapeutic alternatives for CVD is urgently required. Specialized proresolving lipid mediators (SPMs) are bioactive compounds derived from ω-3 and ω-6 fatty acids, integrated into four families: Lipoxins, Resolvins, Protectins, and Maresins. SPMs have generated interest in recent years due to their ability to promote the resolution of inflammation associated with the pathogeneses of numerous illnesses, particularly CVD. Several preclinical studies in animal models have evidenced their ability to decrease the progression of atherosclerosis, intimal hyperplasia, and reperfusion injury via diverse mechanisms. Large-scale clinical trials are required to determine the effects of SPMs in humans. This review integrates the currently available knowledge of the therapeutic impact of SPMs in CVD from preclinical and clinical studies, along with the implicated molecular pathways. In vitro results have been promising, and as such, SPMs could soon represent a new therapeutic alternative for CVD.es
dc.description.urihttps://www.mdpi.com/1422-0067/23/6/3133
dc.identifier.citationInternational Journal of Molecular Sciences, Volume 23, Issue 6, March-2 2022, Article number 3133es
dc.identifier.doi10.3390/ijms23063133
dc.identifier.issn1661-6596
dc.identifier.urihttps://repositorio.unab.cl/xmlui/handle/ria/22932
dc.language.isoenes
dc.publisherMDPIes
dc.rights.licenseAttribution 4.0 International (CC BY 4.0)
dc.rights.urihttps://www.mdpi.com/openaccess
dc.subjectAtherosclerosises
dc.subjectInflammationes
dc.subjectIntimal hyperplasiaes
dc.subjectReperfusion injuryes
dc.subjectResolutiones
dc.subjectSpecialized proresolving mediatorses
dc.titleSpecialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosises
dc.typeArtículoes
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Salazar_Specialized Proresolving Lipid Mediators A Potential Therapeutic Target for Atherosclerosis.pdf
Tamaño:
1.18 MB
Formato:
Adobe Portable Document Format
Descripción:
TEXTO COMPLETO EN INGLES
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
FM - Artículos de Revista